Become a Member to Save

LIVTENCITY▼® (maribavir) dosing summary

LIVTENCITY (maribavir) is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).1
Consideration should be given to official guidance on the appropriate use of antiviral agents.1

This is only a summary for the dosing of LIVTENCITY, please consult the Summary of Product Characteristics for LIVTENCITY before prescribing.

In the pivotal Phase 3 trial, LIVTENCITY delivered double the viraemia clearance (55.7%) compared to investigator-assigned therapy (IAT) (23.9%) – primary endpoint2